Trial Profile
A UK Retrospective Audit of Patients With Crohn's Disease Treated With Infliximab.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 11 May 2022
Price :
$35
*
At a glance
- Drugs Infliximab (Primary)
- Indications Crohn's disease
- Focus Therapeutic Use
- Sponsors Merck Sharp & Dohme Corp.
- 02 Jun 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 17 Dec 2010 Planned end date changed from 1 Nov 2010 to 1 Dec 2010 as reported by ClinicalTrials.gov.
- 18 Nov 2010 Planned end date changed from 1 Oct 2010 to 1 Nov 2010 as reported by ClinicalTrials.gov.